Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

Novo Nordisk is discontinuing one ... Luckily, there are many alternative insulins, both rapid-acting and long-acting. Zilbermint highlights Lantus (insulin glargine) as a good option.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that Novo Nordisk’s long-acting insulin, Tresiba (degludec), is approved for use in Europe.

They also asked Novo Nordisk to explain how patients now on Levemir will get access to "similar long-acting insulin products without gaps in coverage and at similar cost-sharing." Two other ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...

In 1985, Novo Nordisk pioneered production of recombinant human insulin in yeast. In 1999, we introduced rapid-acting and, in 2004, long-acting insulin analogues produced by genetic engineering ...